News | May 13, 2007

New Coalition to Seek Federal Action Against Sudden Cardiac Arrest

May 14, 2007 — More than 25 leading heart advocacy groups have joined to form the Sudden Cardiac Arrest (SCA) Coalition – the very first coalition dedicated to advancing increased research, awareness and educational efforts to address the nation’s number one cardiovascular killer. The Coalition, announced as part of Heart Rhythm 2007, the Society’s 28th Annual Scientific Sessions, will urge Congress and the federal agencies involved in national health policies and programs, to devote more resources to greater public awareness of SCA, research and access to life-saving therapies.

“Sudden Cardiac Arrest is a leading cause of death in this country, taking the lives of more than 250,000 people each year – more than breast cancer, lung cancer, stroke or AIDS,” said Dr. Dwight Reynolds, president of the Heart Rhythm Society, one of the founding members of the SCA Coalition. “It occurs abruptly and without warning, and two-thirds of SCA deaths occur without any prior indications of heart disease. But the truth is that SCA is not always a random event – yet even those of us in the medical community do not always have the tools to properly identify those at risk and prevent attacks.”

To address the public health crisis, the SCA Coalition is made up of advocates from across the spectrum — from physicians and allied health professionals, to patients and caregivers, to first responders and athletic trainers. These groups come together under the Coalition to use their collective strength as a national voice to stop sudden cardiac arrest.

Joined by SCA Coalition members and a local survivor of SCA, Dr. Reynolds spoke of the life-saving possibilities of the Coalition’s work. “As with any public health crisis, the U.S. government and its depth of medical resources offers the best hope for arming the medical community with the research and knowledge it needs, and reaching the American public to provide a level of awareness that can make a difference. The government has already made great strides in research, awareness, and treatment advances for many of our nation’s major health threats – like breast cancer, lung cancer, stroke and AIDS. But now with the passion and hard work of the SCA Coalition, we can focus the government’s attention and significant resources on a killer that takes more lives each year than any of those diseases.”

Over the next year, the SCA Coalition will encourage the introduction and passage of an Omnibus bill that, if passed, will provide the U.S. Department of Health and Human Services with the resources and the imperative to develop and implement a comprehensive education and research program for SCA. This will include appropriations for medical screening and tracking studies, as well as public awareness and education campaigns. The bill will also include a resolution to create a National Sudden Cardiac Arrest Week, to set aside time each year to focus national public attention on this deadly killer.

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init